RECORD // Company

Precision Biosciences Inc

Built 2026-11-21T18:09:00Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Matched by name only, not merged (2)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Precision BioSciences, Inc. · Ctgov · same registered legal name as 'PRECISION BIOSCIENCES INC' Possible match based on name, not a shared identifier. Compare the records. Compare
  • PRECISION BIOSCIENCES, INC. · Epa echo · same registered legal name as 'PRECISION BIOSCIENCES INC' Possible match based on name, not a shared identifier. Compare the records. Compare

6 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-03 · accession 0001628280-26-069092

ItemValuePeriodFormFiledAccessionReport
Revenue$03 months ended 2026-09-3010-Q2026-11-030001628280-26-0690922026-11-21 18:09 UTCReport an error
Net income (loss)$-7,586,0003 months ended 2026-09-3010-Q2026-11-030001628280-26-0690922026-11-21 18:09 UTCReport an error
Interest expense$307,0003 months ended 2026-09-3010-Q2026-11-030001628280-26-0690922026-11-21 18:09 UTCReport an error
Cash and cash equivalents$81,698,000at 2026-09-3010-Q2026-11-030001628280-26-0690922026-11-21 18:09 UTCReport an error
Contract liabilities, current (from an earlier report)$0at 2025-12-3110-K2026-03-120001628280-26-0170192026-11-21 18:09 UTCReport an error
Contract liabilities, noncurrent (from an earlier report)$0at 2025-12-3110-K2026-03-120001628280-26-0170192026-11-21 18:09 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001357874
Ticker
DTIL
CUSIP
74019P207
Record ID
sx:sec:0001357874

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

34 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-21 18:09 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-16SEC EDGAR company profile2026-11-21 18:09 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-21 18:09 UTCReport an error
Fiscal year end (MMDD)05212026-11-16SEC EDGAR company profile2026-11-21 18:09 UTCReport an error
Business address302 EAST PETTIGREW STREET, SUITE A-100, DURHAM, NC, 277012026-11-16SEC EDGAR company profile2026-11-21 18:09 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-21 18:09 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$34,264,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 18:09 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-45,724,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 18:09 UTCReport an error
Total assets (at 2025-12-31)$154,416,0002025-12-3110-K, XBRL Assets2026-11-21 18:09 UTCReport an error
Stockholders' equity (at 2025-12-31)$92,248,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 18:09 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$110,823,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 18:09 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-65,843,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 18:09 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$85,0002025-12-3110-K, XBRL PaymentsToAcquireProductiveAssets2026-11-21 18:09 UTCReport an error
Operating lease liabilities (at 2025-12-31)$6,404,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 18:09 UTCReport an error
Form D total offering amount (D filed 2019-03-15)$70,000,0002019-03-15D2026-11-21 18:09 UTCReport an error
Form D total amount sold (D filed 2019-03-15)$39,550,0002019-03-15D2026-11-21 18:09 UTCReport an error
Form D industry groupBiotechnology2019-03-15D2026-11-21 18:09 UTCReport an error
Form D revenue rangeDecline to Disclose2019-03-15D2026-11-21 18:09 UTCReport an error
Form D date of first sale2019-03-012019-03-15D2026-11-21 18:09 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-09)As previously reported, on November 5, 2026, Precision BioSciences, Inc. (the “Company”) entered into an underwriting agreement relating to the issuance and sale by the Company of 10,235,077 shares of its common stock, $0.000005 par value per share (the “Common Stock”), at a price of $7.75 per share and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase up to 5,893,964 shares of its Common Stock at a price of $7.749995 per pre-funded warrant (the “Offering”). The Company expects net proceeds from the Offering in addition to existing cash and cash equivalents, continued fiscal and operating discipline, and availability of its at-the-market facility will provide…2026-11-09SEC EDGAR 8-K 0001628280-26-071867 (text as filed, excerpt)2026-11-21 18:09 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-06)On November 5, 2026, Precision BioSciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “Underwriters”), in connection with the offering (the “Offering”), issuance and sale by the Company of 10,235,077 shares of its common stock, $0.000005 par value per share (the “Common Stock”), at a price of $7.75 per share and, in lieu of Common Stock to certain investors, pre-funded warrants to purchase up to 5,893,964 shares of its Common Stock at a price of $7.749995 per pre-funded warrant, which represents the per share offering…2026-11-06SEC EDGAR 8-K 0001628280-26-071304 (text as filed, excerpt)2026-11-21 18:09 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-05)On November 5, 2026, Precision BioSciences, Inc. (the “Company”) issued a press release to provide an update on its ELIMINATE-B clinical trial evaluating PBGENE-HBV for chronic hepatitis B (the “HBV News Release”). A copy of the HBV News Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The abstract for the Company’s late-breaking oral presentation at the American Association for the Study of Liver Diseases (“AASLD”) The Liver Meeting® 2026 was published on November 5, 2026 and is furnished as Exhibit 99.2 to this Current Report on Form 8-K (the “PBGENE-HBV Late Breaker Oral Abstract”). On November 5, 2026, the Company also issued a press release to announce the first…2026-11-05SEC EDGAR 8-K 0001628280-26-070542 (text as filed, excerpt)2026-11-21 18:09 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-05)On November 5, 2026, the Company issued the HBV News Release announcing a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026. This presentation includes new and updated preliminary data from the ongoing Phase 1 ELIMINATE-B study of PBGENE-HBV, the first and only in vivo gene editing therapy designed to eliminate cccDNA, the root cause of chronic hepatitis B. The PBGENE Late Breaker Abstract for this presentation was published on November 5, 2026. As of the September 28, 2026 data cutoff date, 25 patients had received a total of 59 administrations of PBGENE-HBV across four dose levels. Key findings include: •Phase 1…2026-11-05SEC EDGAR 8-K 0001628280-26-070542 (text as filed, excerpt)2026-11-21 18:09 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-03)On November 3, 2026, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results and provided a business update for the quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Pursuant to General Instruction B.2 of Current Report on Form 8-K, the information contained in, or incorporated by reference into, this Item 2.02 (including the Press Release attached hereto as Exhibit 99.1) of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…2026-11-03SEC EDGAR 8-K 0001628280-26-069115 (text as filed, excerpt)2026-11-21 18:09 UTCReport an error
Largest institutional holder #1 (13F as filed): Aberdeen Group plc$17,529,1992026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 18:09 UTCReport an error
Largest institutional holder #2 (13F as filed): Bleichroeder LP$15,862,9732026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 18:09 UTCReport an error
Largest institutional holder #3 (13F as filed): Octagon Capital Advisors LP$10,611,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 18:09 UTCReport an error
Largest institutional holder #4 (13F as filed): BOOTHBAY FUND MANAGEMENT, LLC$10,579,5912026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 18:09 UTCReport an error
Largest institutional holder #5 (13F as filed): BlackRock, Inc.$9,218,7822026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 18:09 UTCReport an error
Largest institutional holder #6 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$8,773,6542026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 18:09 UTCReport an error
Largest institutional holder #7 (13F as filed): Lynx1 Capital Management LP$7,470,6632026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 18:09 UTCReport an error
Largest institutional holder #8 (13F as filed): Driehaus Capital Management LLC$7,441,1172026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 18:09 UTCReport an error
Largest institutional holder #9 (13F as filed): Empery Asset Management, LP$6,100,0912026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 18:09 UTCReport an error
Largest institutional holder #10 (13F as filed): Affinity Asset Advisors, LLC$5,082,0872026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 18:09 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.